FDA boots Wellbutrin generic

Share this article:

Generic Wellbutrin got yet another knock for lack of bioequivalence. This time, however, the FDA found that a 300mg tablet made by Actavis was the problem.

Regulatory Focus reports that the FDA posted a note on its website dated Oct. 10 that found the generic antidepressant was not the bioequivalent of GlaxoSmithKline's Wellbutrin. The FDA said the Actavis formulation “had different formulation design as the reference product so that the generic product releases earlier in the gastrointestinal (GI) tract.”

The FDA found a Wellbutrin generic made by Impax and distributed by Teva failed the bioequivalence test in 2012. This finding was based on reports that started to flow into the regulator in 2007.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.